A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Study Summary

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Conditions

Advanced or Metastatic Solid Tumors Breast Cancer Ovarian Cancer Prostate Cancer Endometrial Cancer Colorectal Cancer Head and Neck Cancers Extensive Stage Small Cell Lung Cancer (ES-SCLC)NSCLC

Interventions / Drugs

IDE-161 Pembrolizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment216 participants

Primary Completion—

Lead SponsorIDEAYA Biosciences

Data Retrieved2026-04-11 04:16:36.812063+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.